Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024

Jazz Pharmaceuticals to present five abstracts at ESMO Congress 2024, including new data on zanidatamab for HER2-positive mGEA and mCRC, and Zepzelca for relapsed SCLC.